Infectious Disease Therapeutics Market by Drug (Antibiotics, Antifungal Drugs, Antiparasitic Drugs), Route of Administration (Intravenous, Oral, Topical), Disease, Distribution Channel, End-User - Global Forecast 2024-2030

Infectious Disease Therapeutics Market by Drug (Antibiotics, Antifungal Drugs, Antiparasitic Drugs), Route of Administration (Intravenous, Oral, Topical), Disease, Distribution Channel, End-User - Global Forecast 2024-2030


The Infectious Disease Therapeutics Market size was estimated at USD 116.21 billion in 2023 and expected to reach USD 121.27 billion in 2024, at a CAGR 4.41% to reach USD 157.28 billion by 2030.

Global Infectious Disease Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Disease Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Disease Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Allergan PLC, Amgen Inc., Astellas Pharma US, Inc., AstraZeneca PLC, Bayer AG, BioCryst Pharmaceuticals, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Chimerix, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Chemical Group Corporation, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug
Antibiotics

Antifungal Drugs

Antiparasitic Drugs

Antiviral Drugs

Route of Administration
Intravenous

Oral

Topical

Disease
Hepatitis

HIV

Influenza

Malaria

Tuberculosis

Distribution Channel
Offline

Online

End-User
Homecare Facilities

Hospitals & Clinics

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Disease Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Disease Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Infectious Disease Therapeutics Market?
4. What is the market share of the leading vendors in the Infectious Disease Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Infectious Disease Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Infectious Disease Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of infectious disease across the globe
5.1.1.2. Government initiatives and prompt actions to reduce the burden of infectious disease
5.1.1.3. Increasing number of patent expirations and entry of generic drugs
5.1.2. Restraints
5.1.2.1. Adverse health outcomes of infectious disease drugs
5.1.3. Opportunities
5.1.3.1. Surging investments for development of new drugs to treat infectious diseases
5.1.3.2. Recent advances in immunotherapies against infectious disease
5.1.4. Challenges
5.1.4.1. Availability of alternative treatments for infectious disease management
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Infectious Disease Therapeutics Market, by Drug
6.1. Introduction
6.2. Antibiotics
6.3. Antifungal Drugs
6.4. Antiparasitic Drugs
6.5. Antiviral Drugs
7. Infectious Disease Therapeutics Market, by Route of Administration
7.1. Introduction
7.2. Intravenous
7.3. Oral
7.4. Topical
8. Infectious Disease Therapeutics Market, by Disease
8.1. Introduction
8.2. Hepatitis
8.3. HIV
8.4. Influenza
8.5. Malaria
8.6. Tuberculosis
9. Infectious Disease Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Offline
9.3. Online
10. Infectious Disease Therapeutics Market, by End-User
10.1. Introduction
10.2. Homecare Facilities
10.3. Hospitals & Clinics
11. Americas Infectious Disease Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Infectious Disease Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.
10. South Korea
12.
11. Taiwan
12.
12. Thailand
12.
13. Vietnam
13. Europe, Middle East & Africa Infectious Disease Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.
10. Nigeria
13.
11. Norway
13.
12. Poland
13.
13. Qatar
13.
14. Russia
13.
15. Saudi Arabia
13.
16. South Africa
13.
17. Spain
13.
18. Sweden
13.
19. Switzerland
13.
20. Turkey
13.
21. United Arab Emirates
13.
22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Alexion Pharmaceuticals, Inc.
15.1.3. Allergan PLC
15.1.4. Amgen Inc.
15.1.5. Astellas Pharma US, Inc.
15.1.6. AstraZeneca PLC
15.1.7. Bayer AG
15.1.8. BioCryst Pharmaceuticals, Inc.
15.1.9. Biogen Inc.
15.1.
10. Boehringer Ingelheim GmbH
15.1.
11. Bristol-Myers Squibb Company
15.1.
12. Celgene Corporation
15.1.
13. Chimerix, Inc.
15.1.
14. Eli Lilly and Company
15.1.
15. Gilead Sciences, Inc.
15.1.
16. GlaxoSmithKline PLC
15.1.
17. Johnson & Johnson Services, Inc.
15.1.
18. Merck & Co., Inc.
15.1.
19. Mitsubishi Chemical Group Corporation
15.1.
20. Mylan N.V.
15.1.
21. Novartis AG
15.1.
22. Novo Nordisk A/S
15.1.
23. Pfizer Inc.
15.1.
24. Sanofi S.A.
15.1.
25. Takeda Pharmaceutical Co. Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS
FIGURE 7. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 12. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings